Assay development toward Infliximab therapeutic monitoring by LCMS: new strategy using CDR-peptide selective proteolysis nSMOL

Takashi Shimada

[P25-7-5] Assay development toward Infliximab therapeutic monitoring by LCMS: new strategy using CDR-peptide selective proteolysis nSMOL

Takashi Shimada¹, Noriko Iwamoto², Atsushi Yonezawa³, Kazuo Matsubara⁴ (1.Shimadzu Corporation, 2.Shimadzu Corporation, 3.Kyoto University, 4.Kyoto University Hospital)

キーワード：Infliximab, Antibody drug, nSMOL, LCMS, Bioanalysis

Abstract password authentication.
Password to view abstracts and 'Participants' page is announced on the e-blast sent to early-bird/advanced registrants on September 13. It is also on the page 7 of IATDMCT 2017 PROGRAM BOOK.

講演情報

[P25-7] P25-7: Immunosuppressive drugs (2): Monoclonal antibody and genotyping

[P25-7-5] Assay development toward Infliximab therapeutic monitoring by LCMS: new strategy using CDR-peptide selective proteolysis nSMOL

パスワード